[an error occurred while processing this directive] | [an error occurred while processing this directive]
Efficacy of postoperative three-dimensional conformal radiotherapy in transitional cell carcinoma of the renal pelvis or ureter
LI Xiao-mei, WANG Qing-guo, ZHAO Qing, LI Hong-zhen, ZHANG Min, HOU Zhen-liang, QIN Shang-bin, GAO Xian-shu
Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China Corresponding author:WANG Qing-guo, Email:wangqgzone@sohu.com
Abstract Objective To evaluate the role of postoperative three-dimensional conformal radiotherapy (3DCRT) in transitional cell carcinoma of the renal pelvis or ureter. Methods We retrospectively reviewed a series of 103 patients with transitional cell carcinoma of the renal pelvis or ureter. All patients received surgery without distant metastases and had T3 or T4 disease, or grade 3 disease if T2. No patient received chemotherapy. Thirty-seven patients received three-dimensional conformal radiotherapy (3DCRT) following surgery. Sixty-six patients received surgery alone. The local control rates and survival rates were calculated by Kaplan-Meier method and compared by Logrank test in univariate analysis. Cox regression was used for multivariate analysis. Results The follow-up rates were 89% and 92% in surgery alone and 3DCRT groups. The number of patients who had minimal followed-up time of 5 years were 33,37 in surgery alone and 3DCRT groups. The 1-,3-, and 5-year local control rates were 89% vs. 94%, 74% vs. 90%, and 72% vs. 90% in surgery alone and 3DCRT groups, respectively (χ2=3.90,P=0.048). The 1-,3-, and 5-year bladder tumor-free survival rates were 87% vs. 94%, 60% vs. 79%, and 57% vs. 79% in surgery alone and 3DCRT groups, respectively (χ2=4.50,P=0.037). The 1-,3-, and 5-year overall survival rates were 90% vs. 84%, 71% vs. 65%, and 65% vs. 62% in surgery alone and 3DCRT groups, respectively (χ2=0.32,P=0.573). Univariate and multivariate analyses showed that T stage, lymph node metastasis, positive surgical margin were correlated with overall survival rate (χ2=7.91,64.69,40.20 and 5.08,17.23,8.22,P=0.005,0.000,0.000 and 0.024,0.000,0.004). Conclusions 3DCRT may improve local control and reduce tumor recurrence in bladder in patients with locally advanced transitional cell carcinoma of the renal pelvis or ureter. However, 3DCRT does not improve overall survival in this group of patients.
LI Xiao-mei,WANG Qing-guo,ZHAO Qing et al. Efficacy of postoperative three-dimensional conformal radiotherapy in transitional cell carcinoma of the renal pelvis or ureter[J]. Chinese Journal of Radiation Oncology, 2012, 21(2): 152-155.
LI Xiao-mei,WANG Qing-guo,ZHAO Qing et al. Efficacy of postoperative three-dimensional conformal radiotherapy in transitional cell carcinoma of the renal pelvis or ureter[J]. Chinese Journal of Radiation Oncology, 2012, 21(2): 152-155.
[1] Munoz JJ, Ellison LM. Upper tract urothelial neoplasms:incidence and survival during the last 2 decades. J Urol,2000,164:1523-1525. [2] Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy:a series fromthe upper tract urothelial carcinoma collaboration. Cancer,2009,115:1224-1233. [3] Tan LB, Chang LL, Cheng KI, et al. Transitional cell carcinomas of the renal pelvis and the ureter:comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU International,2008,103:312-316. [4] Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol/Hematol,2003,47:155-169. [5] Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol,2007,4:432-443. [6] Catton CN, Warde P, Gospodarowicz MK, et al. Transitional cell and ureter carcinoma of the renal pelvis outcome and patterns of relapse in patients treated with postoperative radiation. Ural Oncol,1996,2:171-176. [7] Ozsahin M, Zouhair A, Villà S, et al. Prognostic factors in urothelial renal pelvis and ureter tumours:a multicentre rare cancer network study. Eur J Cancer,1999,35:738-743. [8] Maulard-Durdux C, Dufour B, Hennequin C, et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract:no impact on survival? J Urol,1996,155:115-117. [9] Cozad SC, Smalley SR, Austenfeld M, et al. Transitional cell carcinoma of the renal pelvis or ureter:patterns of failure. Urology,1995,46:796-800. [10] 胡克,侯晓荣,沈捷,等.47例输尿管移行细胞癌术后辅助放疗疗效与预后分析.中华放射肿瘤学杂志,2010,19:247-249. [11] Chen B, Zeng ZC, Wang GM, et al. Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer,2011,11:297. [12] Raman JD, Ng CK, Boorjian SA, et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma:predictive factors and pathology. BJU Int,2005,96:1031-1035. [13] Terakawa T, Miyake H, Muramaki M, et al. Risk factorsfor intravesical recurrence after surgical management of transitional
cell carcinoma of the upper urinary tract. Urology,2008,71:123-127. [14] Williams CB,Mitchell JP．Carcinoma of the ureter-a review of 54 cases．Br J Uml,1973,45:377-387. [15] Kang CH,Yu TJ,Hsieh HH,et al．The development of bladder tumoTs and contralateml upper urinary tmct tumor8 ner primary transitional cell carcinoma of the upper urinary tract．Cancer,2003,98:1620-1626. [16] Audenet F, Yates D, Cussenot O, et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol,2011,In press. [17] Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma:results from the upper tract urothelial carcinoma collaboration. J Urol,2009,182:900-906. [18] Rouprêt M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas:2011 Update. Eur Urol,2011,59:584-594. [19] Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy forlocally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol,2004,172:1271-1275. [20] Kaag MG, O′Malley RL, O′Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol,2010,58:581-587. [21] Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer,2010,116:2967-2973.
2012, Vol. 21 
